Menu

Newly Discovered Hormone Explains Disease

Patients with neonatal progeroid syndrome lack a glucose-releasing hormone, while people with insulin resistance have an abundance.

Apr 15, 2016
Kerry Grens

WIKIMEDIA, HENRY GRAY (1918) ANATOMY OF THE HUMAN BODYNeonatal progeroid syndrome (NPS) is a rare genetic disease that typically claims patients’ lives in infancy. In exceptional cases, patients can live into adulthood. College student Abigail Solomon of Austin, Texas, is one such patient; her participation in a study published yesterday (April 14) in Cell has led to the discovery of a peptide hormone involved in glucose release.

Researchers seeking to find a cause for Solomon’s condition showed that not only is this hormone, called asprosin, lacking among people with NPS, it is overabundant among people with insulin resistance. Administering an antibody against asprosin to diabetic mice dropped their plasma insulin levels—suggesting the hormone might be a target to treat diabetes.

“This result brought us full circle. We started with an extremely rare genetic disorder, and using information learned from those patients, discovered a new hormone that can be targeted to treat a different disease that affects many more people,” study leader Atul Chopra of Baylor College of Medicine said in a press release.

Asprosin, Chopra’s team found, is produced by fat, which is lacking among those with NPS. The hormone heads to the liver where it prompts glucose release.

Solomon was one of two people with NPS who were analyzed for the study. “Dr. Chopra’s work not only paves the way to find a treatment for people with my disorder—NPS, something I have lived with my entire life—but also a treatment for diabetes,” she said in the statement. “I feel proud and honored to have been given an opportunity to participate in this process.”

 

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!